Postmarketing surveillance of the safety and effectiveness of etanercept in Japan

Takao Koike, Masayoshi Harigai, Shigeko Inokuma, Kazuhiko Inoue, Naoki Ishiguro, Junnosuke Ryu, Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, Koichi Fujii, Bruce Freundlich, Michio Suzukawa

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

Objective. Postmarketing surveillance (PMS) was conducted evaluating safety and effectiveness of etanercept (ETN; Enbrel®) in Japan, following all patients with rheumatoid arthritis (RA) during the conditional approval period of ETN. Methods. Registration of patients from 1,334 medical sites was conducted between March 2005 and April 2007. Patients were followed for 24 weeks; data regarding patients' background, safety, and effectiveness was recorded centrally. Adverse events (AE) and adverse drug reactions (ADR) were coded using the Medical Dictionary for Regulatory Activities. Effectiveness was measured using the Disease Activity Score 28 (DAS28). Results. Of 14,369 patients registered, data collection and evaluation for 7,091 patients by March 2006 is reported. At least 1 AE was observed for 2,173 patients (30.6%); 60% of AE occurred within 8 weeks of starting ETN. Most frequent AE were injection site reaction (n = 377, 5.3%) and rash (n = 228, 3.2%). Serious AE occurred in 403 patients (5.7%); most frequent were pneumonia (n = 59, 0.8%) and interstitial lung disease (n = 42, 0.6%). Pneumonia was the most common specifically important ADR (n = 102, 1.4%). Mean baseline DAS28 was 6.0, which reduced to 4.4 within 4 weeks, and to 3.9 within 24 weeks. The proportion of patients having good or moderate EULAR response measured by DAS28 was 84.1% at Week 24. Effectiveness rates were more favorable in patients concomitantly using methotrexate. Good or moderate EULAR response rate among patients switched from infliximab was 84.9%. Conclusion. This extensive observational trial, including all patients with RA in Japan taking ETN, found ETN to be both effective and well tolerated by Japanese patients with RA. Trial registration: clinicaltrials.gov identifier NCT00503503. The Journal of Rheumatology

Original languageEnglish
Pages (from-to)898-906
Number of pages9
JournalJournal of Rheumatology
Volume36
Issue number5
DOIs
Publication statusPublished - 2009 May
Externally publishedYes

Fingerprint

Japan
Safety
Rheumatoid Arthritis
Drug-Related Side Effects and Adverse Reactions
Etanercept
Pneumonia
Medical Dictionaries
Interstitial Lung Diseases
Rheumatology
Patient Safety
Exanthema
Methotrexate
Injections

Keywords

  • Efficacy
  • Etanercept
  • Japan
  • Postmarketing surveillance
  • Rheumatoid arthritis
  • Safety

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Koike, T., Harigai, M., Inokuma, S., Inoue, K., Ishiguro, N., Ryu, J., ... Suzukawa, M. (2009). Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. Journal of Rheumatology, 36(5), 898-906. https://doi.org/10.3899/jrheum.080791

Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. / Koike, Takao; Harigai, Masayoshi; Inokuma, Shigeko; Inoue, Kazuhiko; Ishiguro, Naoki; Ryu, Junnosuke; Takeuchi, Tsutomu; Tanaka, Yoshiya; Yamanaka, Hisashi; Fujii, Koichi; Freundlich, Bruce; Suzukawa, Michio.

In: Journal of Rheumatology, Vol. 36, No. 5, 05.2009, p. 898-906.

Research output: Contribution to journalArticle

Koike, T, Harigai, M, Inokuma, S, Inoue, K, Ishiguro, N, Ryu, J, Takeuchi, T, Tanaka, Y, Yamanaka, H, Fujii, K, Freundlich, B & Suzukawa, M 2009, 'Postmarketing surveillance of the safety and effectiveness of etanercept in Japan', Journal of Rheumatology, vol. 36, no. 5, pp. 898-906. https://doi.org/10.3899/jrheum.080791
Koike, Takao ; Harigai, Masayoshi ; Inokuma, Shigeko ; Inoue, Kazuhiko ; Ishiguro, Naoki ; Ryu, Junnosuke ; Takeuchi, Tsutomu ; Tanaka, Yoshiya ; Yamanaka, Hisashi ; Fujii, Koichi ; Freundlich, Bruce ; Suzukawa, Michio. / Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. In: Journal of Rheumatology. 2009 ; Vol. 36, No. 5. pp. 898-906.
@article{94b3cd7f7d4344ed8eb29eddf4dffc15,
title = "Postmarketing surveillance of the safety and effectiveness of etanercept in Japan",
abstract = "Objective. Postmarketing surveillance (PMS) was conducted evaluating safety and effectiveness of etanercept (ETN; Enbrel{\circledR}) in Japan, following all patients with rheumatoid arthritis (RA) during the conditional approval period of ETN. Methods. Registration of patients from 1,334 medical sites was conducted between March 2005 and April 2007. Patients were followed for 24 weeks; data regarding patients' background, safety, and effectiveness was recorded centrally. Adverse events (AE) and adverse drug reactions (ADR) were coded using the Medical Dictionary for Regulatory Activities. Effectiveness was measured using the Disease Activity Score 28 (DAS28). Results. Of 14,369 patients registered, data collection and evaluation for 7,091 patients by March 2006 is reported. At least 1 AE was observed for 2,173 patients (30.6{\%}); 60{\%} of AE occurred within 8 weeks of starting ETN. Most frequent AE were injection site reaction (n = 377, 5.3{\%}) and rash (n = 228, 3.2{\%}). Serious AE occurred in 403 patients (5.7{\%}); most frequent were pneumonia (n = 59, 0.8{\%}) and interstitial lung disease (n = 42, 0.6{\%}). Pneumonia was the most common specifically important ADR (n = 102, 1.4{\%}). Mean baseline DAS28 was 6.0, which reduced to 4.4 within 4 weeks, and to 3.9 within 24 weeks. The proportion of patients having good or moderate EULAR response measured by DAS28 was 84.1{\%} at Week 24. Effectiveness rates were more favorable in patients concomitantly using methotrexate. Good or moderate EULAR response rate among patients switched from infliximab was 84.9{\%}. Conclusion. This extensive observational trial, including all patients with RA in Japan taking ETN, found ETN to be both effective and well tolerated by Japanese patients with RA. Trial registration: clinicaltrials.gov identifier NCT00503503. The Journal of Rheumatology",
keywords = "Efficacy, Etanercept, Japan, Postmarketing surveillance, Rheumatoid arthritis, Safety",
author = "Takao Koike and Masayoshi Harigai and Shigeko Inokuma and Kazuhiko Inoue and Naoki Ishiguro and Junnosuke Ryu and Tsutomu Takeuchi and Yoshiya Tanaka and Hisashi Yamanaka and Koichi Fujii and Bruce Freundlich and Michio Suzukawa",
year = "2009",
month = "5",
doi = "10.3899/jrheum.080791",
language = "English",
volume = "36",
pages = "898--906",
journal = "Journal of Rheumatology",
issn = "0315-162X",
publisher = "Journal of Rheumatology",
number = "5",

}

TY - JOUR

T1 - Postmarketing surveillance of the safety and effectiveness of etanercept in Japan

AU - Koike, Takao

AU - Harigai, Masayoshi

AU - Inokuma, Shigeko

AU - Inoue, Kazuhiko

AU - Ishiguro, Naoki

AU - Ryu, Junnosuke

AU - Takeuchi, Tsutomu

AU - Tanaka, Yoshiya

AU - Yamanaka, Hisashi

AU - Fujii, Koichi

AU - Freundlich, Bruce

AU - Suzukawa, Michio

PY - 2009/5

Y1 - 2009/5

N2 - Objective. Postmarketing surveillance (PMS) was conducted evaluating safety and effectiveness of etanercept (ETN; Enbrel®) in Japan, following all patients with rheumatoid arthritis (RA) during the conditional approval period of ETN. Methods. Registration of patients from 1,334 medical sites was conducted between March 2005 and April 2007. Patients were followed for 24 weeks; data regarding patients' background, safety, and effectiveness was recorded centrally. Adverse events (AE) and adverse drug reactions (ADR) were coded using the Medical Dictionary for Regulatory Activities. Effectiveness was measured using the Disease Activity Score 28 (DAS28). Results. Of 14,369 patients registered, data collection and evaluation for 7,091 patients by March 2006 is reported. At least 1 AE was observed for 2,173 patients (30.6%); 60% of AE occurred within 8 weeks of starting ETN. Most frequent AE were injection site reaction (n = 377, 5.3%) and rash (n = 228, 3.2%). Serious AE occurred in 403 patients (5.7%); most frequent were pneumonia (n = 59, 0.8%) and interstitial lung disease (n = 42, 0.6%). Pneumonia was the most common specifically important ADR (n = 102, 1.4%). Mean baseline DAS28 was 6.0, which reduced to 4.4 within 4 weeks, and to 3.9 within 24 weeks. The proportion of patients having good or moderate EULAR response measured by DAS28 was 84.1% at Week 24. Effectiveness rates were more favorable in patients concomitantly using methotrexate. Good or moderate EULAR response rate among patients switched from infliximab was 84.9%. Conclusion. This extensive observational trial, including all patients with RA in Japan taking ETN, found ETN to be both effective and well tolerated by Japanese patients with RA. Trial registration: clinicaltrials.gov identifier NCT00503503. The Journal of Rheumatology

AB - Objective. Postmarketing surveillance (PMS) was conducted evaluating safety and effectiveness of etanercept (ETN; Enbrel®) in Japan, following all patients with rheumatoid arthritis (RA) during the conditional approval period of ETN. Methods. Registration of patients from 1,334 medical sites was conducted between March 2005 and April 2007. Patients were followed for 24 weeks; data regarding patients' background, safety, and effectiveness was recorded centrally. Adverse events (AE) and adverse drug reactions (ADR) were coded using the Medical Dictionary for Regulatory Activities. Effectiveness was measured using the Disease Activity Score 28 (DAS28). Results. Of 14,369 patients registered, data collection and evaluation for 7,091 patients by March 2006 is reported. At least 1 AE was observed for 2,173 patients (30.6%); 60% of AE occurred within 8 weeks of starting ETN. Most frequent AE were injection site reaction (n = 377, 5.3%) and rash (n = 228, 3.2%). Serious AE occurred in 403 patients (5.7%); most frequent were pneumonia (n = 59, 0.8%) and interstitial lung disease (n = 42, 0.6%). Pneumonia was the most common specifically important ADR (n = 102, 1.4%). Mean baseline DAS28 was 6.0, which reduced to 4.4 within 4 weeks, and to 3.9 within 24 weeks. The proportion of patients having good or moderate EULAR response measured by DAS28 was 84.1% at Week 24. Effectiveness rates were more favorable in patients concomitantly using methotrexate. Good or moderate EULAR response rate among patients switched from infliximab was 84.9%. Conclusion. This extensive observational trial, including all patients with RA in Japan taking ETN, found ETN to be both effective and well tolerated by Japanese patients with RA. Trial registration: clinicaltrials.gov identifier NCT00503503. The Journal of Rheumatology

KW - Efficacy

KW - Etanercept

KW - Japan

KW - Postmarketing surveillance

KW - Rheumatoid arthritis

KW - Safety

UR - http://www.scopus.com/inward/record.url?scp=67449102437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67449102437&partnerID=8YFLogxK

U2 - 10.3899/jrheum.080791

DO - 10.3899/jrheum.080791

M3 - Article

VL - 36

SP - 898

EP - 906

JO - Journal of Rheumatology

JF - Journal of Rheumatology

SN - 0315-162X

IS - 5

ER -